Operational Opportunities in Continued Process Validation
|
|
- Roger Hancock
- 5 years ago
- Views:
Transcription
1 Operational Opportunities in Continued Process Validation IFPAC 2015 Tamar Ben-Avi Director, Head of Pharmaceutical Technology Taro Pharmaceuticals, Haifa, Israel
2 Content Introduction Continued Process Validation Concept Method Case study 1 Surprise! Case study 2 Urban legends Case study 3 Show me the money Case study 4- Question Vision Continued Process Validation closure Acknowledgments
3 Introduction Process validation : Collection and evaluation of data, from the process design stage through commercial production, which establishes scientific evidence that a process is capable of consistently delivering quality product. My Boss: After How many batches you know your product/process well? variation, understanding, detecting, responding, and controlling from input through output
4 Continued Process Verification = continual assurance that the process remains in a state of control A system or systems for detecting unplanned departures from the process as designed. detection of undesired process variability
5 Continued Process Validation= continual assurance that the process remains in a state of control How? Adherence to the CGMP requirements, specifically, the collection and evaluation of information and data about the performance of the process, will allow detection of undesired process variability. What tools? Who?..The data should be statistically trended and reviewed by trained personnel What to analyze?..product and process data.relevant process trends and quality of incoming materials or components, in-process material, and finished products.... process parameters and quality attributes
6 Continued Process Verification = continual assurance that the process remains in a state of control What will be gained? If properly carried out, these efforts can identify variability in the process and/or signal potential process improvements. How to implement? Team approach When? Periodically timely manner product life
7 Continued Process Verification=basic cgmp requirements (a) Sampling and testing of in-process materials and drug products, requires that control procedures... be established to monitor the output and to validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product (e) requires that information and data about product quality and manufacturing experience be periodically reviewed to determine whether any changes to the established process are warranted. Ongoing feedback about product quality and process performance is an essential feature of process maintenance.
8 Product and Process Knowledge Continued Process Verification = Knowledge Continuum ISPE Guide Series: PQLI from Concept to Continual Improvement, Part 4 Process Performance and Product Quality Monitoring System
9 Continued Process Verification = Culture of excellence Integrated team approach. Understanding what drives process variation and stability is the core of Lean. Value-added activities. Increase business performance through more stable and shorter cycle time, more consistent and reduced inventory and greater flexibility to respond to market opportunities (competitiveness)
10 Concept Need to create value (Value+Quality=Money) Need to leverage process knowledge. Adherence to requirements - timely response to regulatory requirements is needed. For legacy products - not all CPPs and CMAs are identified. Where development data is available from development - CPP and CQA might have been changed with time (due to post approval changes) Capturing data by going into the lab? - High variability during stage 3 (can it be simulated?) Trials - cost time and money Integrated approach: Commercial production as the ultimate research facility. CQA trending (control charts) in the APR.
11 Method Product prioritization CQA & CPP & CMA & COP & more - identification Analysis methods (Protocol) Database 4 Data collection 5 Statistical analysis 6 Recommendation implementation (report)
12 Method - Products prioritization Priority New Products All Old /Legacy Products Relatively high risk(*) Old/legacy product with major change Number of batches/yr MT 30 (*) Currently based on incidents reports, investigations, complaints. Under implementation - based on incidents reports, investigations, complaints and CQA process capability indexes (from the APR)
13 Case study 1 - Decreasing trend in stability. CL already in use for release evaluation. Risk assessment Prior Knowledge
14 Case study 1 Handling of continuous process data. The more parameters you have the more batches you need.
15 Case study 1 Data analysis P value < indicates that the model is significant. The model explains about 60% of the variation in AVG Diss. The factors : d(0.5), Mean screen delta P (mmwc),mean inlet dewpoint ( C) and AVG Hardness( Kp), were found significant.
16 Case study 2 - When time increase, dissolution decrease.
17 Case study 2 When time increase, dissolution decreases.
18 Case study 3 100% weight sorting. Tight unit weight acceptance limits (tighter than approved). Yield after sorting 90% (~20 batches a year going to waste)
19 Case study 3 No correlation was observed between capsule weight and dissolution rate in the NOR. Weight ranges can be loosen (Gain: 1% ~ 3-5 batches/year)
20 Case study 4 Question the statistical results. Process understanding is a must. * Surface area*fill-o-matic speed - the combination of Fill-o-matic speed at the High level (72) and Surface area at the Low level (6.4) produces low level of dissolution. * PSD*Fill-o-matic speed - the combination of Fill-o-matic speed at the High level (72) and PSD at the Low level (46) produce low level of DISS.
21 Individual Value Individual Value Moving Range Moving Range Process Capability of Assay % - 200mg LSL USL Process Data O v erall C apability LSL 90 Pp 2.56 Target * USL 110 PPL 2.26 PPU 2.86 Sample Mean Sample N 49 Ppk 2.26 C pm * StDev (O v erall) I-MR Chart of Moisture Content of unmilled granulate % LOD - 100,150,200mg NMT - 1 UC L= _ X= LC L= BN O bserv ed Performance Exp. O v erall Performance UC L= % < LSL 0.00 % > USL 0.00 % Total 0.00 % < LSL 0.00 % > USL 0.00 % Total MR= LC L= BN Process Capability of Dissolution 100mg Johnson Transformation I-MR Chart of Mixer Power densification stage - 100mg BN UC L= USL - 18 _ X=17.35 LC L= LSL - 15 Process Data LSL 85 Target * USL * Sample Mean Sample N 300 StDev (O v erall) A fter Transformation LSL* Target* * USL* * Sample Mean* StDev (O v erall)* LSL* transformed data O v erall C apability Pp * PPL 1.27 PPU * Ppk 1.27 C pm * 3 2 UC L= BN MR=0.704 LC L=0 O bserv ed Performance % < LSL 0.00 % > USL * % Total Exp. O v erall Performance % < LSL* 0.01 % > USL* * % Total
22 Continued Process Verification Continual assurance that the process remains in a state of control Culture of excellence cgmp requirements Lean Knowledge Continuum Not - although we are generics. But - because we are generics!
23 Thanks To. Marta Lichtig, Scientific adviser Sharon Levi, Statistician The Technology Champions Yair Satt Ella Katzir Raz Menashe Leonid Polsky Amnon Blumethal Haya Birenbaum Dikla Eyal Ronen Avraham Adi Sasson Our management
Statistics in Validation. Tara Scherder CSO Supply, Arlenda, Inc
Statistics in Validation 05 Arlenda Tara Scherder CSO Supply, Arlenda, Inc IVT Validation Week Philadelphia, PA Oct 7,05 Agenda Evolution of Validation 0 FDA Guidance Why Use Statistics Stage Process Design
More informationA COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION
A COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION By Mark Mitchell, Principal Consultant, Process and Engineering, Pharmatech Associates, Inc. PHARMATECH WHITE PAPER.DOCX
More informationStatistical Questions from CPV Monitoring of Bioreactor Data
Statistical Questions from CPV Monitoring of Bioreactor Data Craig Bernier Principal Statistician Design to Value and Quality Engineering Janssen Pharmaceutical Companies of Johnson and Johnson Individual
More informationA Framework and Case Study for Implementing the New Process Validation Guidance
A Framework and Case Study for Implementing the New Process Validation Guidance Presented By Bikash Chatterjee President and Chief Technology Officer Pharmatech Associates Agenda Introduction Comparing
More informationLifecycle Management of Process Analytical Technology Procedures
Lifecycle Management of Process Analytical Technology Procedures IFPAC 2015 Marta Lichtig Senior Scientist in New Testing Technologies, ACS Member Contents General Comparison : PV guide to NIR model development
More informationManaging Quality in Pharmaceutical Industry Using Six Sigma. Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA
Managing Quality in Pharmaceutical Industry Using Six Sigma Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA Outlines Pharmaceutical Manufacturing Process and Drug Product Quality. Process Excellence Approach
More informationIdentifying and Controlling CPPs and CMAs
March 2018, BioPharm International Publication Identifying and Controlling CPPs and CMAs Thomas A. Little Ph.D. 2/22/2018 President/CEO Thomas A. Little Consulting, BioAssay Sciences 12401 N Wildflower
More informationProcess Validation Guidelines. Report highlights 23 rd February 2018
Process Validation Guidelines Report highlights 23 rd February 2018 Process validation is an important element of pharmaceutical quality system An effective system provides assurance of the continued capability
More informationDaniel Y. Peng, Ph.D.
Using Control Charts to Evaluate Process Variability Daniel Y. Peng, Ph.D. Quality Assessment Lead Office of Process and Facility (OPF) OPQ/CDER/FDA PQRI 205 Annual Meeting North Bethesda, Maryland October
More informationMaintenance Cost Reduction Project
Maintenance Cost Reduction Project Solving Problems with Labor and Maintenance Costs Prepared by: JWS August 4, 2008 Executive Summary ABC and its primary customer DCE have observed a lack luster at best
More informationStage 3 - Process Validation: Measuring what matters
Stage 3 - Process Validation: Measuring what matters Trevor Schoerie - PharmOut A quote. The company that fails is the company that comes to us and says Just tell us what to do and we will do it. The company
More informationProduct Robustness: Reducing Variability and Ensuring Delivery of Superior Quality Products to Patients
Product Robustness: Reducing Variability and Ensuring Delivery of Superior Quality Products to Patients Dafni Bika, Jennifer Walsh and Tara Nestor Global Manufacturing Science and Technology Bristol-Myers
More informationProcess Validation (PV): Designing an Effective PV Program. Mike Porter Compliance Consultant Commissioning Agents Inc.
Process Validation (PV): Designing an Effective PV Program Mike Porter Compliance Consultant Commissioning Agents Inc. (CAI) 24Apr2013 Agenda Process Validation Background Stage 1: Process Design Stage
More informationDaniel Y. Peng, Ph.D.
Using Process Capability to Enhance Product Quality Daniel Y. Peng, Ph.D. Senior Product Quality Reviewer Office of Process and Facility (OPF) OPQ/CDER/FDA IFPAC 2015 Annual Meeting Arlington, Virginia
More informationISPE Annual Meeting 29 October 1 November 2017 San Diego, CA. FDA Perspective on the Use of Process Capability
FDA Perspective on the Use of Process Capability Chunsheng Cai, Ph.D. Office of Process and Facilities Office of Pharmaceutical Quality, CDER, FDA 2017 ISPE Annual Meeting & Expo Disclaimer This presentation
More informationProduct, Process Knowledge & SPC: PV Lifecycle Approach IFPAC January 2016, Arlington, VA
Product, Process Knowledge & SPC: PV Lifecycle Approach IFPAC January 2016, Arlington, VA Naheed Sayeed Manager, Technical Operations Process Validation, Apotex Inc. 1 Process Validation Life Cycle Stage
More informationImplementation of PAT for Real Time Release Testing. Mark Smith Process Analytical Sciences Group Pfizer, Cork
Implementation of PAT for Real Time Release Testing Mark Smith Process Analytical Sciences Group Pfizer, Cork PAT at Pfizer A key enabler for transformational strategies and new quality paradigms 9 Delivering
More informationGraphical Tools - SigmaXL Version 6.1
Graphical Tools - SigmaXL Version 6.1 Basic and Advanced (Multiple) Pareto Charts Multiple Boxplots and Dotplots EZ-Pivot/Pivot Charts Multiple Normal Probability Plots (with 95% confidence intervals to
More informationQUALITY ASSESSMENT METHODS FOR NEW PRODUCT LAUNCHES: PROCESS VALIDATION LIFECYCLE
QUALITY ASSESSMENT METHODS FOR NEW PRODUCT LAUNCHES: PROCESS VALIDATION LIFECYCLE NAHEED SAYEED-DESTA APOTEX INC. CANADIAN SOCIETY FOR QUALITY 9 TH QUALITY CONGRESS SEPTEMBER 7-8, 2017 OUTLINE Introduction
More informationGuidance for Industry Process Validation: General Principles and Practices; A Contract Manufacturing Organization's Approach
May -3, 202 Javits Center New York, NY Guidance for Industry Process Validation: General Principles and Practices; A Contract Manufacturing Organization's Approach Sandra Lueken Director of Quality Baxter
More informationNIRS, PAT, RTR testing EU experience and regulatory perspective
NIRS, PAT, RTR testing EU experience and regulatory perspective Heidelberg, Germany October 2013 European Compliance Academy (ECA) Overview of the presentation General considerations Cases submitted in
More informationPractical Applications of Statistical Methods Under 2011 FDA Process Validation Guidance
Practical Applications of Statistical Methods Under 2011 FDA Process Validation Guidance Abe Germansderfer Associate Director, Quality Control Gilead Sciences 2011 Process Validation Guidance In January
More informationC O N T E N T S. Brief introduction to Six-Sigma. Case development and hands-on exercises. Conclusions. August 9, 2013 Santiago, Chile
TheApplicationof Six-Sigma DMAIC to a Distribution System Edgardo J. Escalante, Ph.D. ITESM México Pan-American Advanced Studies Institute on Modeling, Simulation and Optimization of Globalized Physical
More informationInspection. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory
More informationEFFECTIVE MANAGEMENT OF THE PROCESS VALIDATION LIFECYCLE VALIDATION MASTER PLAN DEVELOPMENT
EFFECTIVE MANAGEMENT OF THE PROCESS VALIDATION LIFECYCLE VALIDATION MASTER PLAN DEVELOPMENT Paul L. Pluta, PhD Journal of Validation Technology Journal of GXP Compliance University of Illinois at Chicago
More informationGuidance for Industry
Guidance for Industry Process Validation: General Principles and Practices U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
More informationPrincipal approach to CPV :
Principal approach to CPV : Integration with Quality Systems & Operating Mechanisms J. Gampfer, Baxalta, Vienna Austria Baxalta Principal Approach to CPV J. Gampfer Page 1 Baxalta Principal Approach to
More informationWHO DRAFT PHARMACEUTICAL DEVELOPMENT FOR MULTISOURCE (GENERIC) PHARMACEUTICAL PRODUCTS
23 April 2008 Quality Assurance Programme Quality Assurance and Safety: Medicines (QSM) Department of Medicines Policy and Standards (PSM) World Health Organization CH-1211 Geneva 27 Switzerland WHO DRAFT
More informationPROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.
Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation
More informationControl Strategy. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 Control Strategy International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Introduction Structure of this session
More informationLifecycle Product Quality Risk Management
Lifecycle Product Quality Risk Management Richard L. Friedman, M.S. Associate Director Office of Manufacturing and Product Quality Office of Compliance IFPAC Annual Meeting (Arlington, VA) January, 21-24,
More informationConveyorized Photoresist Stripping Replacement for Flex Circuit Fabrication
Conveyorized Photoresist Stripping Replacement for Flex Circuit Fabrication Federal Manufacturing & Technologies M. Donahue KCP-613-8239 Published October 2007 Final Report Approved for public release;
More informationISPE s Process Capability Team
4 September 7 INDUSTRY MATURITY IN THE ASSESSMENT AND USE OF PROCESS CAPABILITY Arne Zilian Head MS&T Processes & Standards Novartis Pharma AG Process Validation Statistics Conference 5 September 7 ISPE
More informationRegulatory Assessment
Implementation of ICH Q8, Q9, Q10 Regulatory Assessment International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Presentation Overview Goal
More informationSCIENCE AND RISK BASED APPROACH TO THE PROCESS VALIDATION LINK FROM QUALITY BY DESIGN TO PROCESS VALIDATION.
IJPSR (2016), Vol. 7, Issue 3 (Review Article) Received on 09 September, 2015; received in revised form, 15 December, 2015; accepted, 05 February, 2016; published 01 March, 2016 SCIENCE AND RISK BASED
More informationImplementing Quality by Design Principles and Concepts to Drug Delivery and Formulation Development. S Betterman 15Apr2015
Implementing Quality by Design Principles and Concepts to Drug Delivery and Formulation Development S Betterman 15Apr2015 Agenda Background Implementation Strategy Infrastructure Building Project Application
More informationQbD implementation in Generic Industry: Overview and Case-Study
QbD implementation in Generic Industry: Overview and Case-Study Inna Ben-Anat, QbD Strategy Leader, Teva Pharmaceuticals IFPAC JAN 2013 R&D Three Core Components of QbD and Generic Industry: How Do They
More informationQuality by Design for Legacy Products A Contradiction?
Quality by Design for Legacy Products A Contradiction? Qualification and Verification of Manufacturing Process throughout the Product Life Cycle Dr. Joerg Gampfer WCBP 2015- CASSS Conference Washington
More informationUnderstanding Variation and Statistical Process Control: Variation and Process Capability Calculations
Understanding Variation and Statistical Process Control: Variation and Process Capability Calculations www.nano4me.org 2017 The Pennsylvania State University Process Capability Calculations 1 Outline Variation
More informationInstructor Info: Dave Tucker, LSSMBB ProModel Senior Consultant Office:
Instructor Info: Dave Tucker, LSSMBB ProModel Senior Consultant Office: 321.567.5642 dtucker@promodel.com 1 Understand how simulation models can be utilized within the DMAIC approach Examine a completed
More informationProcess Validation Lifecycle Approach: A Return to Science
Process Validation Lifecycle Approach: A Return to Science PDA New England Chapter / ISPE Boston Chapter Joint Meeting September 16, 2015 Woburn, MA Rusty Morrison Principal Consultant, CAI Consulting
More informationProcess Capability: Practical Challenges to Implementation
Process Capability: Practical Challenges to Implementation [in pharmaceutical manufacturing] 33rd Quality & Productivity Research Conference Tempe, AZ June 16, 2016 Julia O Neill julia.oneill@tunnellconsulting.com
More informationCurrent Industry Practices in Manufacturing Process Validation. Russ Somma PhD
Russ Somma PhD The objectives for validation are: Demonstrate control over the process and finished product. Demonstrate that the process will consistently produce product which meets all specifications
More informationGuidance for Industry Process Validation: General Principles and Practices. F. Hoffman-La Roche, Ltd.
Guidance for Industry Process Validation: General Principles and Practices D M k T k Dr. Mark Tucker, F. Hoffman-La Roche, Ltd. Disclosures I am currently a Senior Technical Advisor at F. Hoffman -La Roche.
More informationQuality by Design, Revolution or Evolution? Wim Oostra
Quality by Design, Revolution or Evolution? Wim Oostra 1993 1998 2007 2009 2013 And many more.. Content Introduction A bit of history Examples A New product Legacy product Today? The triggers The goal
More informationPRESS INFORMATION No. 04/2014 August 2014
PRESS INFORMATION No. 04/2014 August 2014 Atris Information Systems GmbH. Kartaeuserstr. 49. D-79102 Freiburg Experience with System-supported Continued Process Verification by Peter Trochim Since January
More informationUnderstanding and accounting for product
Understanding and Modeling Product and Process Variation Variation understanding and modeling is a core component of modern drug development. Understanding and accounting for product and process variation
More informationMaintenance Cost Reduction Project: Solving Problems with Labor and Maintenance Costs. Prepared by: JWS. August 4, 2008
Maintenance Cost Reduction Project: Solving Problems with Labor and Maintenance Costs Prepared by: JWS August 4, 2008 Executive Summary ABC and its primary customer DCE have observed a lack luster at best
More informationPROCESS VALIDATION Jaap Koster. Pharmaceutical Consultancy Services, All rights reserved.
PROCESS VALIDATION Jaap Koster PROCESS VALIDATION: GENERAL PRINCIPLES AND PRACTICES Process Validation and Drug Quality Effective process validation contributes significantly to assuring drug quality.
More informationThe long anticipated draft of the FDA s
This article provides an overview of the draft guidance, the key changes in relation to the 1987 guidance, and reviews its potential impact on the current industry approaches to science- and risk-based
More informationQuality by Design (QbD)
Evaluating the Critical Quality attributes & Critical Process Parameters-A Case Study-Tablets GMP International Workshop February 20/21, 2008 Mumbai, India Mukund Yelvigi Director, Therapeutic Area Management,
More informationHow to Identify Critical Quality Attributes and Critical Process Parameters
How to Identify Critical Quality Attributes and Critical Process Parameters Jennifer Maguire, Ph.D. Daniel Peng, Ph.D. Office of Process and Facility (OPF) OPQ/CDER/FDA FDA/PQRI 2 nd Conference North Bethesda,
More informationDrug Product Continuous Process Verification A Case Study
Drug Product Continuous Process Verification A Case Study CASSS 2016 Summer CMC 19 July 2016 Tom Damratoski Bristol-Myers Squibb Director, Biologics Drug Product MS&T 1 Drug Product CPV In Practice - 3
More informationKick Off Meeting CoP D-A-CH PAT & LCS
AUTOMATION IN DER PHARMAINDUSTRIE TREIBER, LÖSUNGEN UND TRENDS WAS BEDEUTET DIE ICH/Q8-12 GMP MANUFACTURING PROCESS CONTROL STRATEGY FÜR DIE ZUKÜNFTIGE AUTOMATISIERUNG? ISPE COMMUNITY OF PRACTICE/COP PAT
More informationProcess Performance Analysis for Roche s Pharmaceutical Manufacturing Network
Process Performance Analysis for Roche s Pharmaceutical Manufacturing Network Yiming Peng, Theo Koulis, Jens Lamerz, and Dan Coleman Nonclinical Biostatistics Genentech, A Member of the Roche Group 2017
More informationValidation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness
Validation/Verification of Test Methods An FDA Perspective Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness FD & C Act Overview Definition of drugs What cgmps are Finished Pharmaceuticals cgmp
More informationContinuous Manufacturing: An Industry View
Novartis Pharmaceuticals Continuous Manufacturing: An Industry View Diane Zezza Novartis Pharmaceuticals FDA/PQRI Conference on Advancing Product Quality March 22, 2017 Where are we today? Continuous Manufacturing
More informationCONSIDERATIONS OF CONTINUOUS MANUFACTURING PROCESSES
LCDR Patric Klotzbuecher U.S. FDA/Office of Regulatory Affairs/New York District 3 rd FDA/PQRI Conference on Advancing Product Quality March 22 24, 2017 CGMP AND REGULATORY CONSIDERATIONS OF CONTINUOUS
More informationTHE PROCESS VALIDATION OF TABLET CONTAINING IRBESARTAN 300MG AND HYDROCHLOROTHIAZIDE 12.5mg Zamir Hussain, Baqir Shyum Naqvi & Muhammad Iqbal Nasiri
THE PROCESS VALIDATION OF TABLET CONTAINING IRBESARTAN 300MG AND HYDROCHLOROTHIAZIDE 12.5mg Zamir Hussain, Baqir Shyum Naqvi & Muhammad Iqbal Nasiri Faculty of Pharmacy, Department of Pharmaceutics, Hamdard
More informationLeft to Our Own Devices Design Control & Risk Management Strategies for Combination Products
Left to Our Own Devices Design Control & Risk Management Strategies for Combination Products DR. RICK WEDGE 12 MAR 2018 Overview Definitions Current Regulatory Landscape Design Controls Risk Management
More informationControl strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA
Control strategy and validation Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA 1 Disclaimer The views and opinions expressed in this presentation are those of the speaker and should not
More informationPAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland
PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec 2004 Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland cca@iol.ie 1 FDA Context 1) FDA 5-Part Strategic Plan Protect &
More informationPAT for the On-line Characterization of Continuous Manufacturing Systems
PAT for the On-line Characterization of Continuous Manufacturing Systems Thomas O Connor, Ph.D. Office of Pharmaceutical Science FDA/PQRI Conference: Innovation in Manufacturing and Regulatory Assessment
More informationEffective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs)
Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs) *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! The globalization of the pharmaceutical
More informationFDA Process Validation
Page 1 of 5 Published on Controlled Environments Magazine (http://www.cemag.us) Home > FDA Process Validation FDA Process Validation Wai Wong Working with the New 2011 Guidelines. In January 2011, the
More informationStatistics and Pharmaceutical Quality
Statistics and Pharmaceutical Quality Karthik Iyer (CQE, CSSBB) Senior Policy Advisor CDER/OC/OMPQ January 24 th, 2014 IFPAC * This presentation reflects the views of the author and should not be construed
More informationKEMET Electronics Italia. December 7, 2011
Development of fb Battery Manufacturing Technologies Joint EC / European Green Cars Initiative Workshop 2011 Bruxelles 7 December 2011 December 7, 2011 1 Corporate Statistics Headquarters: Simpsonville,
More informationAudit Validation Programs Like a Champ (When your time is limited!!) Cathelene Compton 12 October 2017
Audit Validation Programs Like a Champ (When your time is limited!!) Cathelene Compton 12 October 2017 FDA 483 Observations 2 FDA 483 Observations 3 FDA 483 Observations 4 Auditing Validation How to cover
More informationcgmp and Regulatory Considerations of Continuous Manufacturing Processes
cgmp and Regulatory Considerations of Continuous Manufacturing Processes LCDR Patric Klotzbuecher U.S. FDA/Office of Regulatory Affairs/New York District 2 nd FDA/PQRI Conference on Advancing Product Quality
More informationSubpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.
FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis
More informationFuture of Question-based Review and Regulatory Submissions
Future of Question-based Review and Regulatory Submissions Robert Iser Associate Director for Policy Development (Acting) Office of Pharmaceutical Science / CDER / FDA FDA/PQRI Conference on Evolving Product
More informationEffective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (COM) COURSE DESCRIPTION
Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (COM) COURSE DESCRIPTION The globalization of the pharmaceutical supply chain has led increased use of Contract Manufacturing
More informationPQLI Control Strategy Model and Concepts
J Pharm Innov (008) :95 104 DOI 10.1007/s147-008-905-1 PRODUCT QUALITY LIFECYCLE IMPLEMENTATION (PQLI) INNOVATIONS PQLI Control Strategy Model and Concepts Bruce Davis Line Lundsberg Graham Cook Published
More informationCurrent Hotspots during CMC Evaluation a European Regulatory Perspective
www.pei.de Current Hotspots during CMC Evaluation a European Regulatory Perspective CMC Strategy Forum Japan 2018 3-4 December, Tokyo Steffen Gross, Head Section monoclonal - and polyclonal Antibodies
More informationICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Keith O. Webber, Ph.D. Sr. Director, Global Regulator Affairs Rx Perrigo Company, plc Q U A L I T Y A F F
More information2nd FDA/PQRI Conference on Advancing Product Quality
2nd FDA/PQRI Conference on Advancing Product Quality Generic Pharma Perspective on the Identification of Critical Quality Attributes and Critical Process Parameters Bruce D. Johnson, Ph.D. Vice President
More informationMoving towards supplier-owned quality
Moving towards supplier-owned quality Lisa Bobich, PhD Sourcing Continuity, Medtronic, Inc. Outline Background Customer incoming inspection Transition to supplier-only inspection Raising the bar Conclusion
More informationBiowaiver Approaches for Solid Oral Dosage Forms in New Drug Applications Poonam R. Delvadia, Ph.D. Division of Biopharmaceutics\ONDP\OPQ\CDER\FDA
Biowaiver Approaches for Solid Oral Dosage Forms in New Drug Applications Poonam R. Delvadia, Ph.D. Division of Biopharmaceutics\ONDP\OPQ\CDER\FDA PQRI BTC Webinar December 06, 2018 DISCLAIMER The presentation
More informationProcess Robustness: Development to Life Cycle Management. Presented By J. Richard Creekmore US Technology Manager AstraZeneca Pharmaceuticals
Process Robustness: Development to Life Cycle Management Presented By J. Richard Creekmore US Technology Manager AstraZeneca Pharmaceuticals Introduction You ve heard it before: Complaints about the robustness
More informationPharmaceutical control strategy what does it mean and how do we apply? Martin Warman, Martin Warman Consultancy Ltd
Pharmaceutical control strategy what does it mean and how do we apply? Martin Warman, Martin Warman Consultancy Ltd How can the words control strategy cause such debate? Means totally different things
More informationValidation of Pharmaceutical Manufacturing Process Focus: APIs.
Validation of Pharmaceutical Manufacturing Process Focus: APIs Validations: Regulatory History (US FDA) Sterilisation 1977 Aseptic processing 1979 Water Systems 1981 Non-sterile Mfg Process 1987 Revised
More informationICH Quality Implementation Working Group POINTS TO CONSIDER
ICH Quality Implementation Working Group POINTS TO CONSIDER ICH-Endorsed Guide for ICH Q8/Q9/Q10 Implementation Document date: 16 June 2011 International Conference on Harmonisation of Technical Requirements
More informationSeptember 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
September 2, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: FDA Draft Guidance: Current Good Manufacturing Practice Interim
More informationApplication of Quality by Design (QbD) in product development. James E. Polli September 16, 2015
Application of Quality by Design (QbD) in product development James E. Polli jpolli@rx.umaryland.edu September 16, 2015 Pharmaceutical Equivalence Same active ingredient(s) Same dosage form Same route
More informationCommonly Seen Drug Product Related Quality Deficiencies
Commonly Seen Drug Product Related Quality Deficiencies 2016 GPhA CMC Workshop Bethesda, MD; May 18, 2016 Geoffrey Wu, PhD, CPH Lieutenant, US Public Health Service Associate Director for Science & Communication
More informationP01 Process Validation Team
P01 Process Validation Team FDA Initiated Process in September Validation 2009 Guidance and the PDA Grown Process from 10 Validation team members Interest to ~35 today Group Two Co leaders and one Project
More informationISPE Product Show Quality Systems in the 21 st Century
ISPE Product Show Quality Systems in the 21 st Century Theresa McCarthy Dr. Byron Mattingly 7 October 2015 3:30 pm 4:30 pm Agenda Introductions What Schools are here today? What Majors? Overview of Quality
More informationSynopsis: FDA Process Validation Guidance
Synopsis: FDA Process Validation Guidance This synopsis is a comparison of the draft version 2008 and the final version 2011 of the U.S. FDA Guidance Process Validation: General Principles and Practices.
More informationThe Power of Data to Accelerate Development of Robust & Scalable Manufacturing Processes
The Power of Data to Accelerate Development of Robust & Scalable Manufacturing Processes Susan Abu-Absi Director, Manufacturing Sciences & Technology Bristol-Myers Squibb Devens, MA USA May 11, 2016 1
More informationCurrent Features of USFDA and EMA Process Validation Guidance
Human Journals Review Article April 2016 Vol.:6, Issue:1 All rights are reserved by Patwekar S.L et al. Current Features of USFDA and EMA Process Validation Guidance Keywords: Pharmaceutical validation,
More informationPROCESS VALIDATION ANSM 2015 FDA 2011
PROCESS VALIDATION ANSM 2015 FDA 2011 PBE-Expert Inc CANADA Training Company Agreement CPMT #0059104 Qualified Consultant At the measure 2 of the Levier Program PBE, Training Company Agreement CPMT #0059104
More informationGMP The Other Side of Chemistry, Manufacturing & Controls (CMC)
Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls
More informationSakura Bloom Tablets P2 Mock
Sakura Bloom Tablets P2 Mock Mock P2 English version Sakura Bloom Tablets Disclaimer This mock provides an example of the contents to be included in CTD 2.3.P.2 Pharmaceutical Development section for a
More informationQuality by Design Facilitating Real Time Release (RTR) Practical Challenges and Opportunities during RTR Implementation
Quality by Design Facilitating Real Time Release (RTR) Practical Challenges and Opportunities during RTR Implementation Carl E. Longfellow Ph.D., Senior Director, New Product and Process Development, Discussion
More informationProcess Validation Guidelines. by Pramote Cholayudth Thai Industrial Pharmacist Association (TIPA)
Process Validation Guidelines by Pramote Cholayudth cpramote2000@yahoo.com Thai Industrial Pharmacist Association (TIPA) September 19, 2016 1 2 Process Validation References Hierarchy Law Regulatory Guidelines
More informationGMP On Site Series. GMP Essentials
GMP On Site Series GMP Essentials GMP Basics Objectives 1. State the critical definitions of the pharmaceutical industry. 2. Describe the law as it applies to various critical functions. 3. State the history
More informationPrequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Tablets
Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: information about the inspection Name of manufacturer Physical address production departments
More informationPrequalification of Medicines Programme
Prequalification of Medicines Programme SOP 408.4 Annex A WHO PUBLIC INSPECTION REPORT Finished Product Manufacturer WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General
More informationQbD and the New Process Validation Guidance
Page 1 of 6 Published on Pharmaceutical Processing (http://www.pharmpro.com) Home > QbD and the New Process Validation Guidance QbD and the New Process Validation Guidance Bikash Chatterjee and Wai Wong,
More informationINTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C
More information